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Evaluation of region selective 
bilirubin-induced brain damage 
as a basis for a pharmacological 
treatment
Matteo Dal Ben1, Cristina Bottin2, Fabrizio Zanconati2, Claudio Tiribelli1 & Silvia Gazzin1
The neurologic manifestations of neonatal hyperbilirubinemia in the central nervous system (CNS) 
exhibit high variations in the severity and appearance of motor, auditory and cognitive symptoms, 
which is suggestive of a still unexplained selective topography of bilirubin-induced damage. By 
applying the organotypic brain culture (OBC: preserving in vitro the cellular complexity, connection 
and architecture of the in vivo brain) technique to study hyperbilirubinemia, we mapped the regional 
target of bilirubin-induced damage, demonstrated a multifactorial toxic action of bilirubin, and used 
this information to evaluate the efficacy of drugs applicable to newborns to protect the brain. OBCs 
from 8-day-old rat pups showed a 2–13 fold higher sensitivity to bilirubin damage than 2-day-old 
preparations. The hippocampus, inferior colliculus and cerebral cortex were the only brain regions 
affected, presenting a mixed inflammatory-oxidative mechanism. Glutamate excitotoxicity was 
appreciable in only the hippocampus and inferior colliculus. Single drug treatment (indomethacin, 
curcumin, MgCl2) significantly improved cell viability in all regions, while the combined (cocktail) 
administration of the three drugs almost completely prevented damage in the most affected area 
(hippocampus). Our data may supports an innovative (complementary to phototherapy) approach for 
directly protecting the newborn brain from bilirubin neurotoxicity.
Neonatal hyperbilirubinemia is a common and benign event in newborns, characterized by an increased level of 
unconjugated bilirubin (UCB), which has antioxidant effects1. The vast majority of UCB exists in the blood bound 
to its carrier protein albumin. However, a small fraction of UCB remains unbound as free bilirubin (Bf), which 
is responsible for the pathological effects on the central nervous system (CNS)2,3. When hyperbilirubinemia is 
left untreated, both bound and unbound forms of bilirubin are elevated, with the fraction of Bf increasing as the 
amount of available albumin decreases4,5. Presently, deaths due to hyperbilirubinemia are rare in Western coun-
tries thanks to the feasibility and efficacy of phototherapy. However, in past years, there has been a resurgence 
of kernicterus (the most severe and permanent form of bilirubin brain toxicity, RC0180; RP0060)6. If added to 
the still occurring severe damage and death in low and mild-incoming countries6, as well as the lifelong risk of 
developing kernicterus experienced by Crigler-Najjar Type I patients (OMIM218800; ORPHA79234; ICD-10: 
E80.5), the consequences of hyperbilirubinemia continue to merit attention, and it is crucial to improve the risk 
assessment and the therapies for this condition.
It is well accepted that the clinical symptoms of bilirubin toxicity in the brain reflect the selective topography 
of bilirubin-induced damage: motor disorders and athetosis (basal ganglia and cerebellum), auditory dysfunction 
(inferior colliculus), and learning impairments (hippocampus and cerebellum)7. Nevertheless, this pathological 
condition still has unexplained variability in the severity and occurrence of the above reported symptoms8. A 
possible reason for this variability has been attributed to the level and duration of hyperbilirubinemia9. As learned 
from other neonatal neurological diseases, alternative explanations exist. As described in Rice and Barone, win-
dows of CNS vulnerability to stimuli have been documented to strongly depend upon the developmental events 
occurring at the time of exposure to a toxicant, rather than before or after, and might influence the outcome10.
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To map bilirubin targets in the post-natal brain during development and to elucidate the mechanisms as a 
basis for possible therapeutic intervention, we used the organotypic brain culture (OBC) technique11 to study 
bilirubin neurotocicity. OBCs are slices of a specific region of the brain that conserve cellular heterogeneity and 
connections12 and exhibit synaptic plasticity and can reveal mechanisms of pathological insults comparable to 
what is obtained in vivo. OBCs are easily grown in vitro thus allowing for direct exposure to outside agents. They, 
therefore, represent an ideal tool to assess ex vivo the effect of a compound such as Bf on a specific CNS region13. 
In addition, OBCs can be prepared from animals at different postnatal ages, thus allowing one to mimic the var-
ious stages of CNS maturation. We also evaluated the use of various drugs aimed at directly protecting the brain 
pharmacologically, as an innovative treatment to be used as a complement to traditional phototherapy. 
Results
Recovery of OBCs in Bf medium. To compare the viability of OBCs in standard medium vs. OBC media 
(see “Methods”) LDH release assay was performed. As shown in Fig. 1, the OBCs showed a significant LDH 
release immediately after slicing (which reflects procedural stress). This initial increase in LDH release decreased 
to normal levels in approximately 5 days (recovery time). No differences in LDH release were observed between 
OBCs cultured in standard vs. OBC media indicating that the modified media does not affect this assay. No dif-
ferences were detected for any brain region or at any post-natal age (data not shown). Based on these results, Bf 
treatment was initiated at day 6 in vitro to allow for the complete recovery of the OBCs.
Regional sensitivity to bilirubin toxicity. Three viability tests were used to extensively follow the damage 
induced by Bf treatment. Each monitored a different typology of damage: membrane leakage (LDH release assay), 
apoptosis induction (Hoechst staining) and impairment of mitochondrial activity (MTT test).
LDH release. OBCs obtained from 2-day-old rat pups (Fig. 2A) did not show statistically significant increases 
in LDH activity at 70-nM Bf (sensitivity threshold, see “Methods” for details). Conversely, 140-nM Bf (toxic con-
centration) resulted in a toxic effect on the hippocampus (Hip: 3.5-fold vs. DMSO, p < 0.01), inferior collicula 
(IC: 3.2-fold vs. DMSO, p < 0.01) and cerebral cortex (Ctx: 4.4-fold vs. DMSO, p < 0.001). When Bf was increased 
to 300-nM (higher level to exacerbate the damage), a dose-dependent effect was observed in the IC and Ctx (2.0- 
and 2.5-fold, respectively, vs. OBCs treated with 140-nM Bf, p < 0.05; and 5.9-fold and 10.8-fold, respectively, vs 
OBCs treated with DMSO, p < 0.001), with the latter showing the maximum damage. No dose effect was observed 
in the Hip (3.8-fold vs. DMSO, p < 0.001). Only at 300-nM Bf concentration was a loss of membrane integrity 
observed in the cerebellum (Cll: 3.3-fold, p < 0.01) and superior collicula (SC: 1.8-fold, p < 0.05).
In OBCs from 8-day-old animals (Fig. 2B), irrespective of the bilirubin concentration, the Hip displayed the 
maximum toxicity, followed by the IC and Ctx. In these three regions, LDH activity was already significantly 
increased after 24 hrs at 70-nM Bf (6.4-, 3.6- and 2.8-fold, respectively, p < 0.001). Increasing bilirubin concen-
tration (140-nM) increased the damage in the Hip, IC and Ctx (to 19.0-, 10.6- and 8.9-fold vs. DMSO, p < 0.001). 
On the contrary, no damage was detected in the Cll and SC at 140-nM Bf. At 300-nM Bf, we did not observe a 
further increase in LDH release in the Hip, IC and Ctx. As in the case of OBCs from 2-day-old animals, statisti-
cally significant changes were present in the Cll (3.6-fold, p < 0.001) and SC (1.8-fold, p < 0.01) after only 24 hrs 
of exposure at 300-nM Bf.
Hoechst staining. The numerical data and a representative picture of the chromatin condensation are shown 
in Fig. 2C and D. In OBCs from 2-day-old rats (Fig. 2C), 70-nM Bf treatment resulted in statistically significant 
apoptosis in only the Hip (2.2-fold vs. control, p < 0.001), with a clear dose effect when increasing Bf to 140-nM 
(2.3-fold vs. OBCs treated with 70, p < 0.05; p < 0.01 vs. OBCs treated with DMSO) and 300-nM Bf (12.0-fold 
vs. OBCs treated with DMSO, p < 0.001). At 140-nM Bf, apoptosis was significant in the Ctx (2.2-fold, p < 0.05), 
without any further increase at 300-nM, and in the IC (10.4-fold, p < 0.01 vs. control, 3.1-fold vs. OBCs treated 
with 70-nM Bf, p < 0.05), again with no change when increasing concentration to 300-nM Bf. Moreover, 300-nM 
Bf was needed to induce apoptosis in the Cll (2.0-fold vs. control, p < 0.05) and SC (4.5-fold vs. control, p < 0.05).
Figure 1. Representative picture of OBC recovery after slicing. Comparison of membrane damages (LDH 
release) in usual OBC medium (solid line) and in Bf-adapted medium (dotted line) after cutting (refer to culture 
medium paragraph in Material and Methods section). The results are expressed as the percentage vs. maximum 
release (day 1). Data are expressed as the mean ± SD of three repetitions.
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Hippocampal slices from more developed animals (P8 – Fig. 2D) confirmed a high sensitivity to the low bil-
irubin dose of 70-nM (p < 0.001), with further increases at both 140 and 300-nM (61-fold vs. control, p < 0.001, 
and 3.7-fold vs. OBCs treated with 70-nM Bf, p < 0.01). The IC was also damaged after each treatment, but with 
Figure 2. Results of viability tests of P2 and P8 OBCs challenged with 70, 140 and 300-nM Bf. (A) LDH 
release in P2 OBCs; (B) LDH release in P8 OBCs; (C) Hoechst staining of P2 OBCs; (D) Hoechst staining of P8 
OBCs; (E) MTT assay of P2 OBCs; (F) MTT assay of P8 OBCs. LDH release and Hoechst are expressed as fold 
change of control (DMSO = 1). MTT is expressed as % change of control (DMSO = 100%). Data are expressed 
as the mean ± SD of three-five repetitions. Statistical significance: (a) p < 0.05, (b) p < 0.01, (c) p < 0.001 vs. 
DMSO; §p < 0.05, §§p < 0.01, §§§p < 0.001 70-nM vs. 140-nM; #p < 0.05, ##p < 0.01, ###p < 0.001 140-nM vs.  
300-nM. Hip: hippocampus; Cll: cerebellum; IC: inferior colliculus; SC: superior colliculus; Ctx: cortex.
www.nature.com/scientificreports/
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a clear dose-dependent effect (2.9-fold at 70-nM, p < 0.01; 17-fold at 140-nM, p < 0.01; and 43-fold vs. OBCs 
treated with DMSO, p < 0.001). No significant bilirubin-induced apoptosis was observed in the Cll or Ctx.
Mitochondrial activity. Despite some change in MTT activity (Fig. 2E), no significant changes were found in 
P2 OBCs exposed to all Bf concentrations, except for a 25% decrease (p < 0.05) in the SC exposed to 140-nM Bf.
In P8 OBCs (Fig. 2F), a significant reduction in mitochondrial metabolism was detected in the Hip (p < 0.001) 
and IC (p < 0.01) exposed to Bf concentrations of 140 and 300-nM. The Ctx and SC showed a significant reduc-
tion in mitochondrial activity only when exposed to the maximal dose (300-nM Bf, both p < 0.05). The Cll was 
insensitive to all Bf concentrations.
Developmental sensitivity to bilirubin toxicity. Because brain exhibits significant post-natal development10, 
two different post-natal ages were compared. To highlight the developmental sensitivity to bilirubin toxicity, 
viability was expressed as a ratio of P8/P2 results (Table 1). A ratio higher than 1-fold indicates an increased 
developmental sensitivity in the LDH assay and Hoechst staining results; the opposite is true for MTT activity.
Developmental sensitivity to membrane leakage. LDH revealed a clear age-related increase in the sensitivity to 
bilirubin in the Hip when exposed to 140 and 300-nM Bf (P8 higher than P2) (both p < 0.001) (Table 1). A similar 
response was observed in the IC (at 140-nM Bf concentration, p < 0.01). No developmental sensitivity to bilirubin 
toxicity was observed in the Cll, SC or Ctx.
Developmental sensitivity to apoptosis. As shown in Table 1, at all bilirubin concentrations, Hip sensitivity was 
increased in P8 vs. P2 OBCs (p < 0.01 at 70-nM Bf and p < 0.001 at 140 and 300-nM Bf), while in the IC, an 
increase in apoptosis was observed at only the highest concentration (p < 0.001). No developmental difference 
was observed in the Cll, SC or Ctx.
Developmental sensitivity to in mitochondrial activity. Despite a trend of decrease in the Hip, IC and Ctx, no 
significant differences in the mitochondrial activity in these regions were observed (Table 1, lower panel).
Screening of pathways of damage. Different analyses (histological, genomic, and enzymatic) were per-
formed in OBCs treated with bilirubin to screen for biomolecular mechanisms of damage. Screening was per-
formed at the post-natal age showing the maximal sensitivity (P8) and at the toxic Bf concentration of 140 nM 
for 24 hrs.
Hematoxylin and Eosin. The damage to the Hip observed in the previously described viability tests was con-
firmed by histological evaluation. Tissue damage was evidenced by the appearance of large intracellular spaces, 
neuronal cell loss, apoptosis and some degree of necrosis. Edema, fibrosis, the presence of foam cells and micro-
gliosis were also observed (see Fig. 3B = bilirubin treatment vs. A = control). Similar to the Hip, but to a lesser 
extent, the IC showed large intracellular spaces, apoptotic bodies and foam cells (Fig. 3H). Cellular death was also 
present in the Ctx (decreased cellular density, with a generalized weak nuclear staining – Fig. 3N). Some degree 
of degeneration was also present in the Cll, with peri-cellular edema, necrosis, and a slight detectable increase in 
apoptosis (Fig. 3E). The SC was only marginally affected by the exposure to bilirubin, with a negligible increase 
of cells with vacuoles and fibrillary matrix components with cellular debris, with respect to DMSO-exposed 
organotypic SC cultures (Fig. 3K).
Hip Cll IC SC Ctx
LDH
 70 nM 7.11 1.12 2.20 1.43 2.40
 140 nM 5.44c 0.79 3.35b 1.51 2.03
 300 nM 5.51c 1.12 1.61 1.22 0.85
Hoechst
 70 nM 8.95b 0.61 0.89 0.13 0.77
 140 nM 12.70c 0.75 1.65 1.68 2.92
 300 nM 4.97c 0.65 4.19c 0.51 0.12
MTT
 70 nM 0.85 1.17 0.96 1.12 1.04
 140 nM 0.69 1.18 0.86 1.27 0.78
 300 nM 0.64 0.95 0.71 0.83 0.57
Table 1.  Developmental sensitivity to bilirubin toxicity: the P8/P2 ratio of viability tests. Lactate 
dehydrogenase release (LDH - upper), Hoechst staining of apoptotic bodies (middle) and mitochondrial 
activity (MTT - lower) were expressed as the ratio of P8 results divided by P2 results. A ratio greater than 1 
demonstrates an increased sensitivity during the development for LDH and Hoechst data, the opposite for the 
MTT test. Statistical significance vs. DMSO ap < 0.05; bp < 0.01; cp < 0.001. Hip: hippocampus; Cll: cerebellum; 
IC: inferior colliculus; SC: superior colliculus; Ctx: cortex.
www.nature.com/scientificreports/
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Quantitative real-time PCR analysis of markers of damage. To evaluate the possible pathway of damage triggered 
by bilirubin in each region, we assessed the expression of selected genes as markers of specific biomolecular pro-
cesses of damage (Table 2).
Oxidative imbalance was revealed in all regions with the exception of the Ctx. A 2.5- to 4-fold increase in 
expression of the inducible heme oxygenase-1 (HO-1) (a marker of oxidative stress) was detected in the Hip, IC 
(both p < 0.001), Cll (p < 0.01) and SC (p < 0.05). Sulfiredoxin 1 (Srnx1, involved in antioxidant metabolism, and 
Figure 3. Histological analyses of the recovery of OBCs challenged with 140-nM Bf after treatment with 
cocktail. Images of H&E staining of OBCs treated with DMSO (A,D,G,J,M), 140 nM Bf (B,E,H,K,N) or cocktail 
(C,F,I,L,O) of Hip (A,B,C), Cll (D,E,F), IC (G,H,I), SC (J,K,L) and Ctx (M,N,O). Red arrow: apoptosis. Green 
arrow: microgliosis. Red circle: foam cells. Red square: fibrosis. Green circle: inflammation. Blue square: edema. 
Hip: hippocampus; Cll: cerebellum; IC: inferior colliculus; SC: superior colliculus; Ctx: cortex. Scale Bar 50 μ m.
www.nature.com/scientificreports/
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induced in response to an oxidant milieu) was maximally modulated in the Hip and IC (p < 0.001 and p < 0.05, 
respectively), followed by the SC and Cll (p < 0.01 and p < 0.05, respectively).
The activation of the inflammatory pathway was assessed by the expression of multiple cytokines. Tumor 
necrosis factor alfa (Tnfα) mRNA was significantly induced in only the Hip and SC (p < 0.05 and p < 0.001, 
respectively). Interleukin 1β (Il1β) was maximally altered in the IC (p < 0.001), followed by the Hip (p < 0.01), 
Cll and SC (both p < 0.05).
The most striking alteration involved the interleukin 6 (Il6) and the cyclooxygenase (Cox2) genes, which were 
up-regulated approximately 300- and 50-fold, respectively, in the Hip and 100- and 60-fold, respectively, in the 
IC (all p < 0.001). In the third most damaged area (Ctx), Il6 expression was up-regulated approximately 12.4-fold 
(p < 0.001), with Cox2 expression up-regulated approximately 3.5-fold (p < 0.05). Both genes were modulated in 
the Cll (both p < 0.001) and in the SC (both p < 0.05).
Glutamate release in culture medium. The involvement of the glutamate excitotoxicity pathway was assessed by 
the quantification of glutamate release into the culture media (Table 2). Significant release was detected in the 
Hip, 2.4-fold (p < 0.001), and IC, 2.0-fold (p < 0.01), after bilirubin treatment.
Evaluation of possible therapeutic approaches. Finally, we used the OBCs as a screening platform to 
identify neuroprotective therapeutics. The LDH test was chosen to evaluate the protective effect of each treatment 
because of the level of sensitivity to Bf-induced damage that this test exhibited (Fig. 4). The main rationale for 
the drugs selected in this work was based on their potential to be used safely as new therapeutic treatments in 
severely jaundiced newborns14; therefore, only drugs already in clinical use, and known to cross the blood brain 
barrier were considered. The maximal dose not inducing adverse effects was experimentally identified, starting 
from the information available in literature for each compound. The current gold-standard drug treatment for 
bilirubin-based neurotoxicity, minocycline15,16, has been shown to suppress cerebellar hypoplasia in the Gunn 
rat17, the animal model for Crigler-Najjar type I and kernicterus. Minocycline was also effective in restoring 
Bf-induced damage in OBCs (Hip − 35%, IC − 80% and Ctx − 57%, all p < 0.001) (Fig. 4). Curcumin, an antiox-
idant nutraceutical18,19, improved the viability of the challenged OBCs by approximately 69% (p < 0.001) in the 
IC, 43% (p < 0.01) in the Ctx and 18% (p < 0.05) in the Hip. MgCl2, a glutamate receptor blocker20,21, effectively 
improved viability by approximately 47% (p < 0.01), 44% (p < 0.01) and 37% (p < 0.001) in the Ctx, IC and Hip, 
respectively. Indomethacin, an anti-inflammatory drug22,23, increased the viability of OBCs by 63% (p < 0.01), 
60% (p < 0.001) and 42% (p < 0.001) in the Ctx, IC and Hip, respectively. The cocktail of the 3 compounds greatly 
improved viability in the Hip (78%, p < 0.001 vs. Bf), while no additional difference in respect to single drugs was 
observed in the Ctx or IC (62%, 68%; both p < 0.001 vs. Bf). Exposure to a single drug or to the cocktail for 24 hrs 
did not increase LDH release in the OBCs compared to the DMSO control, indicating the safety of the dosage 
used in our system.
Assessment of the damage improvements after treatment. As a final demonstration of drug effi-
cacy, both the histological examination (Fig. 3C,F,I,L,O) and quantification of the markers of biomolecular path-
ways of damage were performed using the cocktail as stated above (Table 3).
In agreement with the viability improvement evidenced by the LDH release results, the cocktail approach 
coincided with a significant recovery in all the 3 damaged regions (Hip, IC and Ctx; Fig. 3C,I and O, respectively). 
However, the treatment did not completely reverse the damage due to Bf, as there were still marginal signs of 
damage present. Histological evaluation of Bf-induced damage in OBCs receiving the cocktail revealed a signif-
icant reduction in apoptosis and a moderate reduction of cellular edema in the Hip. The IC showed a reduction 
of edema with a conservation of cellular elements, while the Ctx had a reduction of necrosis and of the fibrotic 
scenario. The SC and Cll images showed slight histologic improvement (Fig. 3).
The observed improvement in the viability was confirmed at the molecular level by real-time PCR. The 
mRNA expression of markers for oxidative imbalance was slightly increased for HO-1 in the Hip (increase of 
Hip Cll IC SC Ctx
Ho1 3.97 ± 1.09c 2.55 ± 0.95b 3.39 ± 0.92c 2.51 ± 0.67a 1.65 ± 0.09
Srnx1 14.90 ± 2.79c 4.38 ± 3.15a 17.42 ± 5.65a 9.12 ± 4.83b 1.44 ± 1.12
Tnfα 3.58 ± 2.17a 2.06 ± 1.3 1.81 ± 0.94 2.25 ± 0.32c 1.08 ± 0.61
Il1β 13.69 ± 7.17b 8.83 ± 6.08a 23.96 ± 10.58c 5.38 ± 2.8c 2.89 ± 1.51a
Il6 305.08 ± 120.22c 9.64 ± 5.04c 98.92 ± 38.35c 122.08 ± 126.10a 12.39 ± 7.61c
Cox2 53.64 ± 11.12c 62.19 ± 29.95c 56.08 ± 21.88c 2.48 ± 2.06a 3.53 ± 2.44a
Glu 2.39 ± 0.31c 1.20 ± 0.25 2.03 ± 0.59b 1.23 ± 0.18 1.21 ± 0.18
Table 2.  Analysis of the markers of biomolecular pathway of damage induced by bilirubin. The expression 
of selected genes, used as markers of biomolecular pathways of damage induced by bilirubin, was expressed 
as fold change of the control (DMSO-challenged OBCs). Similarly, quantification of glutamate release in the 
medium of Bf-challenged OBCs was expressed as the fold change of DMSO-exposed cultures. Ho1: heme 
oxygenase1; Srnx1: sulfiredoxin 1; Tnfα: tumor necrosis factor alfa; Il1β: interleukin 1β ; Cox2: cyclo-oxygenase 
2. Data are expressed as the mean ± SD of three-five repetitions. Statistical significance: ap < 0.05; bp < 0.01; 
cp < 0.001. Hip: hippocampus; Cll: cerebellum; IC: inferior colliculus; SC: superior colliculus; Ctx: cortex.
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approximately 164% vs. bilirubin-treated OBCs, p < 0.01) (Table 3). The other regions did not show a significant 
change in HO-1 expression after treatment with Bf and cocktail.
Treatment with the Bf + cocktail also showed a reduction of interleukin 6 (Il6) and cyclooxygenase 2 (Cox2) 
levels compared to slices exposed to Bf alone, thus indicating that the neuro-inflammatory markers were mod-
ulated by bilirubin treatment (Table 3) and the effect attenuated by the drugs. Cox2 levels decreased by approx-
imately 97% in the Hip, IC and Cll (p < 0.05, p < 0.01 and p < 0.01, respectively). Il6 mRNA was reduced by 
approximately 80–90% in the Hip, IC, Ctx and Cll (all p < 0.01). Similar down-regulation (about of 95% vs. 
bilirubin-treated OBCs) compared to normal expression was also observed for Il1β in the Hip (p < 0.05), IC and 
Cll (both p < 0.01). Less impressive was the reduction of Tnfα expression, which was statistically significant in 
only the SC (p < 0.001).
In accordance with our previous results showing significant glutamate-mediated damage in only the Hip and 
IC, the cocktail significantly reduced glutamate release in these same regions (Hip p < 0.01 and IC p < 0.05).
Figure 4. Viability improvement following treatment with bilirubin and therapeutic agents. Recovery 
from damage (LDH release) in challenged OBCs is expressed as fold change of control (DMSO = 1). Data are 
expressed as the mean ± SD of three-five repetitions. Statistical significance: (a) p < 0.05; (b) p < 0.01;  
(c) p < 0.001. @: p < 0.05 cocktail vs. indomethacin. *p < 0.01 cocktail vs. minocycline; #,$p < 0.001 cocktail vs. 
curcumin and Mg, respectively. OBCs exposed to drugs alone as well as undamaged regions (Cll, SC) exposed 
to cocktail did not display signs of toxicity. Hip: hippocampus; Cll: cerebellum; IC: inferior colliculus; SC: 
superior colliculus; Ctx: cortex.
www.nature.com/scientificreports/
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Discussion
Our data highlight a clear region-specific and developmental regulated in the brain’s sensitivity to bilirubin toxic-
ity. The Hip emerged as the most sensitive brain region, followed by the IC. These data are in agreement with the 
most common clinical manifestations of bilirubin neurotoxicity: alterations in the auditory-evoked potentials24,25 
and memory/learning deficits26,27. Additionally, our findings are in agreement with clinical findings8 that indicate 
damage to the IC and Hip8.
Despite being considered as a region resistant to bilirubin toxicity28, some evidence of bilirubin toxicity in 
the cerebral Ctx has been reported. Newborn electroencephalographic measurements have demonstrated that 
hyperbilirubinemia affects cerebro-cortical electrical activity in a time-limited manner29, and autopsy findings 
have shown apoptosis and necrosis in this area30. Moreover, nearly all in vitro evidence of the mechanisms of 
bilirubin-induced cytotoxicity have been obtained using primary cultures of neurons and astrocytes isolated 
from the cerebral Ctx31,32. In animal models, cortical sensitivity to bilirubin has also been shown by inhibiting the 
phosphorylation of synapsin I26, by observing histological abnormalities in the occipital cortex, and altering the 
balance of excitatory and inhibitory neurotransmitters33. Collectively, these findings suggest a possible cortical 
sensitivity to bilirubin. Though this sensitivity is probably less severe than that observed in other regions, poten-
tial damage to the Ctx likely needs to be considered in infants where bilirubin neurotoxicity is suspected.
Only P8 OBCs were sensitive to a bilirubin concentration of 70-nM (Bf) (Fig. 2), which is considered to 
be either not toxic or at least at the threshold of potentially causing damage3. This observation suggests an 
“age-dependent” sensitivity to bilirubin toxicity. This is in line with what has been reported in animal models 
for hyperbilirubinemia (Gunn rat), where the window of vulnerability to bilirubin toxicity has been observed at 
P6–10, a period preceded and followed by a much lower CNS vulnerability34–36. Unfortunately, no detailed bio-
molecular data are available on postnatal brain development in humans. Conversely, in rodents, the presence of 
a “dormant period” in the first 3 postnatal days has been described37. Thereafter, a sustained increase of NMDA 
receptor subunits38 and sensitivity to inflammation39 are observed in the second postnatal week. Along with 
these changes, the activation of neurogenesis, proliferation of non-neuronal cells, and increased apoptosis and 
remodeling in physiological tissues37 are all potential mechanisms for bilirubin toxicity10, contributing to the final 
toxic phenotype. This is in full agreement with the concept of the vulnerability of the developing brain to a toxic 
substance: “if exposure occurs before or after an organ develops, it is less vulnerable to perturbation than if exposure 
occurs during development of that organ”10, with respect to different brain insults and with our hypothesis that 
CNS sensitivity to UCB might be developmentally regulated.
Also of interest is the insensitivity of the Cll OBCs to acute (24 hrs) bilirubin insult. Cerebellar hypoplasia 
due to bilirubin toxicity is a landmark finding of animal models of hyperbilirubinemia34,36,40–44 and is reported in 
pre-term babies45,46. In our model, we found regions of the brain susceptible to an acute exposure (24 hrs) to UCB 
(Hip, IC) and others that are not. Specifically, for the Cll, our results suggest that a longer (chronic) exposure to 
toxic levels of UCB may be required to initiate the damage in this CNS region. This finding is in line with what has 
been reported in animal models. In both Gunn rats and UGT− /− mice, cerebellar damage took at least 7–9 days 
to become significant and was not detectable at early post-natal ages, despite the presence of hyperbilirubinemia 
early after birth34,36,40–44. Also in line with this hypothesis is the observation that 4 days of exposure to 140-nM Bf 
increased LDH release (> 2.0-fold) in our Cll OBCs (data not shown).
In this study, we discovered a multifactorial etiology of bilirubin toxicity by cross-validating the data obtained 
from the analysis of mechanisms of damage (Table 3 and Fig. 3) and treatments (Fig. 4). Neuroinflammation 
(revealed by cytokine modulation – Table 3 and microgliosis – Fig. 3) and oxidative stress (Ho1/Srnx1 modula-
tion – Table 3, and foam cells observed in Fig. 3) were observed in all three damaged areas (Hip, IC and Ctx), with 
glutamate release present in only the Hip and IC OBCs (Fig. 3). Additionally, our findings regarding the neuro-
logical damage in Hip, IC and Ctx are in agreement with the histological findings at autopsy30,45. A part being in 
agreement with the literature based on cell lines and the animal model that we used as reference (see M&M), the 
pro-inflammatory action of bilirubin we observed well agreed with the two unique previous studies using cerebel-
lar and hippocampal OBCs40,47. The discrepancy in the glutamate finding (not investigated in the Hip47, showing a 
temporary significant release in Cll OBCs exposed to UCB40, but never significant in the Cll in our acute scheme) 
Hip Cll IC SC Ctx
Ho1 164.26b 90.20 101.92 110.61 100.94
Srnx1 106.6 61.58 51.96 45.65 31.84
Tnfα 33.72 91.05 91.46 32.12c 62.61
Il1β 4.42b 27.01 4.26b 6.99b 20.84
Il6 17.67b 11.09b 7.62b 1.16 7.65b
Cox2 2.60a 4.91b 2.25b 71.99 40.00
Glu 58.53b 94.52 66.14a 98.04 116.14
Table 3.  Restoration of marker genes levels and glutamate release after cocktail treatment. The expression 
of selected genes/glutamate release was expressed as % of gene expression compared with the same sample 
challenged with bilirubin. Ho1: heme oxygenase1; Srxn1: sulfiredoxin 1; Tnfα: tumor necrosis factor alfa; Il1β: 
interleukin 1β ; Cox2: cyclo-oxygenase 2; Glu: glutamate. Data are expressed as the means of three-five biological 
repetitions. Statistical relevance: ap < 0.05; bp < 0.01; cp < 0.001. Hip: hippocampus; Cll: cerebellum; IC: inferior 
colliculus; SC: superior colliculus; Ctx: cortex.
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might be explained by the different experimental set-ups, and with the amount of Bf used (20-nM in Barateiro 
et al.40 vs. 140-nM in. our work) being the major difference.
In less damaged regions, single drugs were effective in reducing tissue damage. Curcumin and indomethacin 
emerged as the most effective drugs in ameliorating the damage in the IC with similar results for indomethacin 
in the Ctx. In these regions, all therapeutic schemes applied matched with the protection offered by minocycline 
(Fig. 4), a drug shown to be fully effective in in vivo models of kernicterus15,16. Notably, in addition to the anti-
oxidant and anti-inflammatory mechanisms, minocycline most likely acts as a chelator for bivalent ions, such 
as calcium which is probably strongly relevant in bilirubin encephalopathy, as demonstrated by Daood et al.48. 
However, minocycline use is not allowed in neonates due to its side effects, and safe calcium chelators are still not 
available in clinics. In agreement with the multifactorial pathway of damage, drugs applied as a cocktail seem to 
be to the most effective way to ameliorate the damage in the Hip, the most damaged region both in our experi-
mental model and in newborns. Indeed, the additive effect of the cocktail vs. single drug administration (Fig. 4) 
indicates that bilirubin acts simultaneously on different, but not necessarily connected, pathways. Importantly, 
we observed no evidence of drug toxicity in damaged (Hip, IC and Ctx) or undamaged (Cll, SC) brain regions 
after exposure to either the single or cocktail drug treatments, indicating that the cocktail is potentially a more 
effective treatment to confer the maximum and widespread protection to the brain in severe hyperbilirubinemia.
In conclusion, the application of OBCs to study bilirubin neurotoxicity proved well-suited for the reproduc-
tion of findings observed in vivo and clinically. We have demonstrated a multifactorial toxic action of bilirubin, 
with some regional specificity, and we have shown ex vivo the efficacy of a new theoretical approach aimed at 
protecting the brain with drugs that are currently used in the clinical setting.
Methods
Organotypic brain culture preparation. Wistar HanTM Rats, at 2 (P2) and 8 (P8) days after birth, were 
obtained from the animal facility of the University of Trieste. Animal experiments were performed according to 
the Italian Law (decree 87–848) and European Community directive (86-606-ECC). The study was approved by 
the animal care and use committee of the University of Trieste, along with regular communication with the Italian 
Ministry. Maximal effort was used to minimize the number of the animals used and their suffering, with the 
respect to the 3R rule. Immediately after sacrifice, the Hip, Cll, IC (all pathologically involved in kernicterus)28, 
SC and Ctx (considered resistant) were dissected and maintained in dissection medium (ice cold Gey’s Balanced 
Salt Solution plus D-Glucose 10 mg/mL) until use. A McIIwain tissue chopper (Gomshall Surrey, U.K.) was used 
to cut transversely 300 (SC, IC), 350 (Hip, Ctx) and 425 (Cll) μ m slices. Healthy slices, selected for structural 
integrity under stereomicroscope inspection, were maintained in dissection medium for 60 min to allow clear-
ing of cutting surfaces from preparation procedure stress. Slices were then transferred to sterile, semi-porous 
Millicell-CM inserts (PICM03050, Millipore, Darmstadt, Germany), fed by 1 mL of media and maintained at 
37 °C, 5% CO2, 95% humidity in a humidified incubator11.
Cultures medium. Standard culture medium (50% Basal Medium Eagle – BME - medium, 25% Hank’s 
Balanced Salt Solution - HBSS, 25% Heat-Inactivated Horse Serum, 1% L-Glutamine, 2% Penicillin/Streptomycin, 
10 mg/mL glucose)11 was modified to allow for Bf quantification. Bf adapted medium (OBCs medium) was com-
posed of 65% Basal Medium Eagle (Life Technologies Corporation, Grand Island, NY), 10% heat-inactivated 
Fetal Bovine Serum (Euroclone, Milan, Italy), 25% Hank’s Balanced Salt Solution (Sigma Aldrich, St. Louis, MO, 
USA), 1% L-Glutamine (Life Technologies Corporation, Grand Island, NY), 2% Penicillin/Streptomycin (Life 
Technologies Corporation, Grand Island, NY), 10 mg/mL D-Glucose (Sigma Aldrich, St. Louis, MO, USA). The 
media was changed the day after cutting and every two days thereafter. Slices were maintained in culture 5 days 
before starting Bf exposure, this amount of time was required to allow recovery from the stress of slicing (Fig. 1)49.
Bf treatment. After 6 days in vitro, slices were challenged for 24 hrs with different bilirubin concentrations 
based on our experience in vitro31,43,47 and in the range of the in vivo brain Bf 50. The concentration of UCB dis-
solved in DMSO required to reach the desired Bf concentrations in the OBC medium was quantified according to 
Roca et al.51. Three concentrations of Bf were used: 70-nM (sensitivity threshold), 140-nM (toxic concentration), 
300-nM (higher level to exacerbate the damage). Control slices were exposed to the same final concentration of 
DMSO used to dissolve the UCB.
Viability tests. Lactate dehydrogenase release. The amount of total extracellular LDH in media, indica-
tive of membrane leakage, was determined using a CytoTox-ONE™ Homogeneous Membrane Integrity Assay 
(G7891, Promega, Madison, WI, USA). After Bf exposure (24 hrs), the supernatant was collected, and the reaction 
was carried out according to the manufacturer’s instructions. The fluorescence (560Ex/590Em) was determined 
using an EnSpire Multimode Plate Reader (PerkinElmer, Waltham, MA, USA), and the background fluorescence 
subtracted. The amount of LDH released in treated slices was expressed as the fold change compared to the con-
trol slices.
Hoechst staining. Evidence of chromatin condensation, a marker of cell death by apoptosis, was obtained by 
administration of 1 μ g/mL Hoechst 33258 (Sigma Aldrich, St. Louis, MO, USA). Slices treated with Bf or DMSO 
alone were fixed for 30 min at room temperature in 3% paraformaldehyde (PFA)13. Apoptotic cells were counted 
at 40X magnification, by fluorescence microscopy using a Leica DM2000 (Leica Mycrosystems Srl, Solms, 
Germany) by three separate individuals. At least three different fields were analyzed in each repetition. The results 
were expressed as the percentage of apoptotic cells relative to the total number (apoptotic plus unaffected) of cells 
in the control (100%).
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Mitochondrial activity. Mitochondrial metabolic activity was assessed using a 1-(4,5-dimethylthiazol-2-yl)-3, 
5-diphenylformazan (MTT) assay (Sigma-Aldrich, St. Louis, MO, USA). Post-challenge experiments, slices for 
each repetition were incubated with 0.5 mg/mL of MTT in media at 37 °C for 1 hr, harvested, and the precipitated 
salt dissolved in DMSO. Absorbance was detected at 562 nm using a LD 400C Luminescence Detector (Beckman 
Coulter, Milan, Italy). The results were expressed as the percentage of activity relative to controls (100%).
Screening of pathway of damage. Histology. After Bf treatment, OBCs were immediately fixed in neu-
tral buffered formalin and embedded in 4% paraffin. Tissue were sectioned to a thickness of 3 μ m by a microtome 
(Microm-hm 340e- BioOptica, Milan, It), and dried in oven a 60 °C for one hour. Sections were stained with 
hematoxylin & eosin (H&E) using a Leica ST5020 Multistainer (Leica Microsystem, Milano, It). Histology was 
read by two independent pathologists, blinded to experimental design and treatment groups, at the Department 
of Pathology of Academic Medical Center Hospital of Cattinara. Images were collected by a D-Sight plus image 
digital microscope & scanner (Menarini Diagnostics, Firenze, Italy).
Quantitative real-time PCR of selected markers of bilirubin toxicity. Genes reported to be involved in the bio-
molecular pathways of neuronal damage were selected as markers of these pathway47,49,52–56 (see Table 4). The 
mRNA expression of the genes of interest was analyzed by quantitative real-time PCR. Total RNA was extracted 
using TRI Reagent® RNA Isolation Reagent (Sigma-Aldrich, St. Louis, MO, USA), following the manufac-
turer’s instructions. Complementary DNA (cDNA) was synthesized with the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Monza, Italy). For the quantitative real-time PCR, primers were designed 
using the Beacon designer 4.2 software (Premier Biosoft International, Palo Alto, CA, USA) on rat sequences 
available in GenBank (Table 1). The reaction was performed in a final volume of 15 μ L in an iQ5 Bio-Rad Thermal 
cycler (BioRad Laboratories, Hercules, CA, USA). Briefly, 25 ng of cDNA and the corresponding gene-specific 
sense/antisense primers (250 nM each, with the exception of Cyclo-Oxygenase 2 -Cox2 and Interleukin 1β -Il1β, 
500 and 750 nM, respectively) were diluted in the Sso Advance SYBER green supermix (Bio-Rad Laboratories, 
Hercules, CA, USA). Amplification of target genes was accomplished using the following protocol: 3 min at 95 °C, 
40 cycles at 95 °C for 20 sec, 60 °C for 20 sec, and 72 °C for 30 sec. The specificity of the amplification was verified 
by a melting-curve analysis, and non-specific products of PCR were not found in any case. The relative quan-
tification was made using the iCycleriQ software, version 3.1 (Bio-Rad Laboratories, Hercules, CA, USA) by 
the Δ Δ Ct method, taking into account the efficiencies of the individual genes and normalizing the results to 
the housekeeping genes (Hypoxanthine guanine phosphoribosyl transferase: Hprt, Glyceraldehyde 3-phosphate 
dehydrogenase: Gapdh)57,58.
Glutamate quantification in culture media. The amount of extracellular glutamate (glu), a marker of 
bilirubin-induced excitotoxicity31,59,60, was quantified using a Glutamate Assay Kit (MAK004, Sigma-Aldrich, 
St. Louis, MO, USA). Briefly, after the Bf exposure, the supernatant was collected, and the assay was performed 
according to the manufacturer’s instructions. The absorbance (450 nm), proportional to the glutamate present, 
was determined using an EnSpire Multimode Plate Reader (PerkinElmer, Waltham, MA, USA). Glutamate release 
in media was expressed as fold change compared to the control slices.
Screening of therapeutic drugs. Slices from P8 animals (the most sensible post-natal age), were exposed 
(for 24 hrs) to the following: (1) DMSO alone, as control; (2) 140 nM Bf–to induce the damage; (3) drugs alone–to 
assess possible toxic effects; (4) 140 nM Bf plus single drugs; and (5) 140 nM Bf plus the three principles simul-
taneously (cocktail). Drugs screened in this study included the following: curcumin, an antioxidant (50 μ M, 
Sigma-Aldrich, St. Louis, MO, USA), magnesium chloride, a glutamate channel blocker, (10 mM, Sigma-Aldrich, 
St. Louis, MO, USA) as alternative to the bilirubin displacer magnesium sulfate14 already used in newborns, and 
indomethacin, an anti-inflammatory agent (50 μ M, Liometacen, Promedica Srl. Parma, Italy). Minocycline was 
used at 60 μ M (Sigma-Aldrich, St. Louis, MO, USA).
Gene Accession number Forward primer 5′-3′ Reverse primer 3′-5′ Amplicon length (bp)
Hprt NM_012583.2 AGACTGAAGAGCTACTGTAATGAC GGCTGTACTGCTTGACCAAG 163
Gapdh NM_017008.2 CTCTCTGCTCCTCCCTGTTC CACCGACCTTCACCATCTTG 87
Ho1 NM_012580.2 GGTGATGGCCTCCTTGTA ATAGACTGGGTTCTGCTTGT 76
Srxn1 NM_001047858.3 AAGGCGGTGACTACTACT TTGGCAGGAATGGTCTCT 85
Tnfα NM_012675.2 CAACTACGATGCTCAGAAACAC AGACAGCCTGATCCACTCC 172
IL1β NM_031512.2 AACAAGATAGAAGTCAAGA ATGGTGAAGTCAACTATG 137
IL6 NM_012589.1 GCCCACCAGGAACGAAAGTC ATCCTCTGTGAAGTCTCCTCTCC 161
Cox2 NM_017232.3 CTTTCAATGTGCAAGACC TACTGTAGGGTTAATGTCATC 92
Table 4.  Primer specifications. Primer sequences designed for the mRNA quantification. Hprt hypoxanthine 
guanine phosphoribosyltransferase, Gapdh glyceraldehyde 3-phosphate dehydrogenase, Hmox1 Heme 
oxygenase 1, Sxrn1 sulfiredoxin 1, Tnfα tumor necrosis factor alpha, Il1β interleukin 1 beta, Il6 interleukin 6, 
Cox2 cyclooxygenase 2.
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Statistical analysis. Data were analyzed with GraphPad Prism version 5.00 for Windows (GraphPad 
Software, La Jolla California USA). Statistical significance was evaluated by paired two-tailed test. ANOVA 
was applied to the results in Table 2, where different post-natal ages have been compared. A p value < 0.05 was 
considered as statistically significant. The results are expressed as the mean ± SD of at least three independent 
repetitions.
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